Real‐world performance of plasma p‐tau181 in a heterogeneous memory clinic cohort
Annals of Clinical and Translational Neurology · 2024
DOI: 10.1002/acn3.52116 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2024. Verfasst von Tandis Parvizi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: tau Proteins, Alzheimer Disease, Cognitive Dysfunction, Biomarkers. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: F. Hoffmann-La Roche Ltd.
Abstract (Originalsprache)
Objective
In light of clinical trials and disease‐modifying therapies, an early identification of patients at‐risk of developing Alzheimer's disease (AD) is crucial. Blood‐based biomarkers have shown promising results regarding the in vivo detection of the earliest neuropathological changes in AD. Herein, we investigated the ability of plasma p‐tau181 to act as a prescreening marker for amyloid positivity in a heterogeneous memory clinic‐based cohort.
Methods
In this retrospective cross‐sectional study, we included a total of 115 patients along the clinical AD continuum (mild cognitive impairment [MCI] due to AD, n = 62, probable AD dementia, n = 53). Based on their biomarker status, they were stratified into an amyloid‐positive (Aβ+, n = 88) or amyloid‐negative cohort (Aβ−, n = 27). Plasma and CSF p‐tau181 concentrations were quantified using an ultrasensitive single‐molecule array (SIMOA©). Furthermore, age‐ and sex‐adjusted receiver operating characteristic (ROC) curves were calculated and the area under the curve (AUC) of each model was compared using DeLong's test for correlated AUC curves.
Results
The median (interquartile range [IQR]) concentration of plasma p‐tau181 was significantly higher in Aβ+ patients (3.6 pg/mL [2.5–4.6]), compared with Aβ− patients (1.7 pg/mL [1.2–1.9], p < 0.001). Regarding the distinction between Aβ+ and Aβ− patients and the prediction of amyloid positivity, a high diagnostic accuracy for plasma p‐tau181 with an AUC of 0.89 (95% CI = 0.82–0.95) was calculated. Adding the risk factors, age and APOE4, to the model did not significantly improve its performance.
Interpretation
Our findings demonstrate that plasma p‐tau181 could be a noninvasive and feasible prescreening marker for amyloid positivity in a heterogeneous clinical AD cohort and therefore help in identifying those who would benefit from more invasive assessment of amyloid pathology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Medical University of Vienna, Vienna, Austria.
- Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.
- Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria.
- Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
ORCID-Profile: Tandis Parvizi, Raphael Wurm, Patrick Altmann, Ellen Gelpi, Elisabeth Stögmann
Förderung
- F. Hoffmann-La Roche Ltd
Zitieren
APA
Parvizi, T., Wurm, R., König, T., Silvaieh, S., Altmann, P., Klotz, S., Regelsberger, G., Traub-Weidinger, T., Gelpi, E., & Stögmann, E. (2024). Real‐world performance of plasma p‐tau181 in a heterogeneous memory clinic cohort. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.52116
Vancouver
Parvizi T, Wurm R, König T, Silvaieh S, Altmann P, Klotz S, et al. Real‐world performance of plasma p‐tau181 in a heterogeneous memory clinic cohort. Annals of Clinical and Translational Neurology. 2024. doi:10.1002/acn3.52116
BibTeX
@article{Parvizi2024,
author = {Parvizi, Tandis and Wurm, Raphael and König, Theresa and Silvaieh, Sara and Altmann, Patrick and Klotz, Sigrid and Regelsberger, Guenther and Traub-Weidinger, Tatjana and Gelpi, Ellen and Stögmann, Elisabeth},
title = {Real‐world performance of plasma p‐tau181 in a heterogeneous memory clinic cohort},
journal = {Annals of Clinical and Translational Neurology},
year = {2024},
doi = {10.1002/acn3.52116}
}
EUVIMED